Abbie [Coo_老虎社区_美港股上老虎

VVTZ
2021-12-10

Abbie [Cool]

AbbVie Shares Rise; Wells Fargo Lauds Growth Prospects

AbbVie (ABBV) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of t

AbbVie Shares Rise; Wells Fargo Lauds Growth Prospects

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":605357672,"tweetId":"605357672","gmtCreate":1639120203620,"gmtModify":1639120203620,"author":{"id":3582629808245810,"idStr":"3582629808245810","authorId":3582629808245810,"authorIdStr":"3582629808245810","name":"VVTZ","avatar":"https://static.tigerbbs.com/2a29e08a133febe21814a6f15264733d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Abbie <span>[Cool]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p>Abbie <span>[Cool]&nbsp;</span></p></body></html>","text":"Abbie [Cool]","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/605357672","repostId":1101852117,"repostType":4,"repost":{"id":"1101852117","kind":"news","pubTimestamp":1639115859,"share":"https://www.laohu8.com/m/news/1101852117?lang=&edition=full","pubTime":"2021-12-10 13:57","market":"us","language":"en","title":"AbbVie Shares Rise; Wells Fargo Lauds Growth Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=1101852117","media":"TheStreet","summary":"AbbVie (ABBV) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of t","content":"<p>AbbVie&nbsp;(<b>ABBV</b>)&nbsp;shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of the pharmaceutical titan at overweight on strong growth prospects.</p>\n<p>He also named it a top pick and has a $165 share-price target.</p>\n<p>AbbVie recently traded at $123.54, up 1%. It has climbed 15% year to date, trailing the S&amp;P 500’s 25% gain.</p>\n<p>While many investors and analysts are focusing on the loss of exclusivity for AbbVie’s rheumatoid arthritis drug, Humira, the “strong growth prospects” of the company’s other treatments are “not yet fully appreciated,” Bansal wrote.</p>\n<p>“Our head-to-head analysis suggests that ABBV's ex-Humira business is bigger and growing faster than Eli Lilly&nbsp;(<b>LLY</b>)&nbsp;but is trading at 15 times estimated 2022 earnings.” That’s more than a 50% discount to Lilly, he said.</p>\n<p>AbbVie has industry-leading 20% compound-annualized growth for earnings per share based on 2021-25 estimates for its non-Humira business, Bansal said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie Shares Rise; Wells Fargo Lauds Growth Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie Shares Rise; Wells Fargo Lauds Growth Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 13:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/abbvie-initiated-overweight-rating-wells-fargo-on-growth-prospects><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbbVie (ABBV) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of the pharmaceutical titan at overweight on strong growth prospects.\nHe also named it a top pick and ...</p>\n\n<a href=\"https://www.thestreet.com/investing/abbvie-initiated-overweight-rating-wells-fargo-on-growth-prospects\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.thestreet.com/investing/abbvie-initiated-overweight-rating-wells-fargo-on-growth-prospects","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101852117","content_text":"AbbVie (ABBV) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of the pharmaceutical titan at overweight on strong growth prospects.\nHe also named it a top pick and has a $165 share-price target.\nAbbVie recently traded at $123.54, up 1%. It has climbed 15% year to date, trailing the S&P 500’s 25% gain.\nWhile many investors and analysts are focusing on the loss of exclusivity for AbbVie’s rheumatoid arthritis drug, Humira, the “strong growth prospects” of the company’s other treatments are “not yet fully appreciated,” Bansal wrote.\n“Our head-to-head analysis suggests that ABBV's ex-Humira business is bigger and growing faster than Eli Lilly (LLY) but is trading at 15 times estimated 2022 earnings.” That’s more than a 50% discount to Lilly, he said.\nAbbVie has industry-leading 20% compound-annualized growth for earnings per share based on 2021-25 estimates for its non-Humira business, Bansal said.","news_type":1,"symbols_score_info":{"ABBV":0.9}},"isVote":1,"tweetType":1,"viewCount":1524,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

AbbVie Shares Rise; Wells Fargo Lauds Growth Prospects

评论（3）

热议股票